Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top and bottom lines, with revenue of $37.7M vs. $42.2M expected and a GAAP EPS loss of $0.03 vs. the $0.005 loss expected. While the Acute Care franchise grew 43.9% YoY, the Oncology segment declined 15.9% due to legal uncertainty surrounding CINVANTI. Management has withdrawn FY26 guidance and is exploring strategic alternatives, significantly increasing the risk profile.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Heron Therap(HRTX) the Revenue is 37.67 M (+1.25%), Miss estimate;the EBIT is -2.044 M (-24.86%), Miss estimate;the EPS is -0.03 (-50%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.04B1.25%
0.04B13.44%
-0.00B12.19%
EBITMiss expectations
-0.00B24.86%
0.00B176.36%
-0.00B201.22%
EPSMiss expectations
-0.0350.00%
-0.00575.00%
-0.0250125.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf